Insulet Co. (NASDAQ:PODD) Shares Purchased by Ethic Inc.

Ethic Inc. raised its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 44.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,462 shares of the medical instruments supplier's stock after acquiring an additional 1,678 shares during the period. Ethic Inc.'s holdings in Insulet were worth $1,426,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PODD. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet during the fourth quarter valued at about $36,000. Itau Unibanco Holding S.A. acquired a new position in shares of Insulet in the fourth quarter valued at approximately $42,000. SRS Capital Advisors Inc. grew its holdings in shares of Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in shares of Insulet in the fourth quarter valued at approximately $57,000. Finally, Assetmark Inc. grew its holdings in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have commented on PODD shares. Royal Bank of Canada began coverage on shares of Insulet in a research report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price objective on the stock. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a research note on Monday, April 28th. Barclays upped their price objective on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Stifel Nicolaus raised their price target on Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Finally, Citigroup boosted their target price on shares of Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $306.53.

Insider Buying and Selling at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares of the company's stock, valued at $7,382,134.60. This represents a 18.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This represents a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Price Performance

Shares of Insulet stock traded up $2.73 on Friday, hitting $324.75. The company's stock had a trading volume of 836,387 shares, compared to its average volume of 708,259. Insulet Co. has a 52-week low of $170.67 and a 52-week high of $326.10. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a fifty day moving average price of $262.55 and a 200-day moving average price of $265.81. The company has a market capitalization of $22.85 billion, a P/E ratio of 56.09, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The company had revenue of $569.00 million for the quarter, compared to analyst estimates of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm's quarterly revenue was up 28.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.73 EPS. On average, equities research analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.